In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.
Gilead's oncology segment is expanding, with Trodelvy and Yescarta showing potential for accelerated revenue growth. Despite risks like Medicare price caps and emerging competitors, Gilead's ...
Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.
Results that may be inaccessible to you are currently showing.